Allergan PLC plans to lay off more than 1,000 workers as the drugmaker works to restructure its business ahead of sales declines expected for several key products, including blockbuster dry-eye drug Restasis.
Allergan, which has about 18,000 employees world-wide, said Wednesday in a regulatory filing that the job cuts will affect employees in its commercial operations and other functions. It also plans to eliminate about 400 open positions. Allergan didnâ€™t specify the geographic regions where it planned to reduce employment.
... To Read the Full Story Subscribe Sign In